Comparative Pharmacology
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus INTRAROSA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DIETHYLSTILBESTROL versus INTRAROSA.
DIETHYLSTILBESTROL vs INTRAROSA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic nonsteroidal estrogen that binds to estrogen receptors (ERα/ERβ), activating estrogen-responsive gene transcription, leading to proliferation of estrogen-sensitive tissues.
Intrarosa (prasterone) is an exogenous dehydroepiandrosterone (DHEA) that is converted locally to androgens and estrogens, primarily testosterone and estradiol, in vaginal cells. It restores the hormonal environment of the vaginal tissue, improving epithelial integrity and reducing symptoms of vulvovaginal atrophy.
0.5-2 mg orally once daily for palliative treatment of advanced prostate cancer; 5-15 mg orally once daily for prevention of postpartum breast engorgement.
6.5 mg administered intravaginally once daily at bedtime for 21 days.
None Documented
None Documented
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24 hours (range 20-30 hours) in adults; prolonged in hepatic impairment.
Terminal elimination half-life is approximately 3.5 hours, allowing for twice-daily dosing in maintenance therapy.
Primarily renal (90% as glucuronide and sulfate conjugates), with less than 5% excreted unchanged in urine; biliary/fecal elimination accounts for about 10%.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose; biliary/fecal elimination accounts for the remaining 40%, with minimal hepatic metabolism.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."